Modulation of Retinal Atrophy With Rituximab in Multiple Sclerosis
- 8 April 2021
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology
- Vol. 96 (20) , e2525-e2533
Abstract
Objective To investigate the effects of rituximab on retinal atrophy in patients with relapsing-remitting multiple sclerosis (RRMS), we performed serial optical coherence tomography (OCT) scans among a cohort of patients with RRMS on rituximab and compared rates of ganglion cell + inner plexiform layer (GCIPL) atrophy to those observed among age- and sex-matched glatiramer acetate (GA)–and natalizumab-treated patients with RRMS and healthy controls (HCs). Methods In this observational study, patients with RRMS treated with a single disease-modifying therapy and HCs were followed with serial OCT for a median duration of 2.8 years. Participants with uncontrolled hypertension, diabetes mellitus, or glaucoma, and eyes with optic neuritis ≤6 months prior to baseline OCT, or during follow-up, were excluded. Statistical analyses were performed using linear mixed-effects regression. Results During the overall follow-up period, rates of GCIPL atrophy were −0.28 ± 0.11 µm/y among rituximab-treated patients with RRMS (n = 35). This was similar to GA-treated (n = 49; −0.33 ± 0.05 µm/y; p = 0.69) and natalizumab-treated patients (n = 88; −0.17 ± 0.10 µm/y; p = 0.13) and faster than HCs (n = 78; −0.15 ± 0.03 µm/y; p = 0.006). Rituximab-treated patients exhibited 0.55 ± 0.23 µm/y faster rates of GCIPL atrophy during the first 12 months of treatment, relative to afterwards (n = 25; p = 0.02), during which period GCIPL atrophy rates were −0.14 ± 0.13 µm/y. Conclusions Retinal atrophy in RRMS is modulated by rituximab. Greater attenuation of retinal atrophy may occur after 12 months of rituximab treatment, following which time GCIPL atrophy rates are similar to those observed among natalizumab-treated patients with RRMS and HCs. Our findings raise the possibility that the neuroprotective therapeutic response with rituximab in RRMS may take up to 12 months, which should be confirmed by larger studies. Classification of Evidence This study provides Class IV evidence on the difference in rate of change of the GCIPL thickness in patients with RRMS comparing rituximab to other disease-modifying therapies.Keywords
This publication has 23 references indexed in Scilit:
- Defining the clinical course of multiple sclerosisNeurology, 2014
- Retinal layer segmentation of macular OCT images using boundary classificationBiomedical Optics Express, 2013
- Clinical effects of natalizumab on multiple sclerosis appear early in treatment courseJournal of Neurology, 2013
- The OSCAR-IB Consensus Criteria for Retinal OCT Quality AssessmentPLOS ONE, 2012
- Visual dysfunction in multiple sclerosis correlates better with optical coherence tomography derived estimates of macular ganglion cell layer thickness than peripapillary retinal nerve fiber layer thicknessMultiple Sclerosis Journal, 2011
- Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteriaAnnals of Neurology, 2011
- Rituximab add-on therapy for breakthrough relapsing multiple sclerosisNeurology, 2010
- Reproducibility of high-resolution optical coherence tomography in multiple sclerosisMultiple Sclerosis Journal, 2010
- B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple SclerosisNew England Journal of Medicine, 2008
- A Controlled Trial of Natalizumab for Relapsing Multiple SclerosisNew England Journal of Medicine, 2003